Clinical Research

Reports

Sign in Create free account

Amgen Inc.

Address
1 Amgen Center Drive

Sponsor Overview

assignment
90
sponsored trials
science
76
molecules
location_city
1600
research centres
public
26
countries
person_search
3154
investigators

Specializations

Oncology and Hematologic Malignancies

Amgen Inc. funds research across a broad oncology portfolio spanning non-small cell lung cancer, small cell lung cancer, metastatic castration-resistant prostate cancer, gastric and gastroesophageal junction cancer, colorectal cancer, melanoma, acute lymphoblastic leukemia, and solid tumors with molecular targets such as KRAS p.G12C and MTAP deletion.

  • Advanced solid tumors
  • KRAS-altered cancers
  • Small cell lung cancer
  • Prostate cancer
  • Hematologic malignancies

Its cancer research also includes biomarker-defined disease groups such as FGFR2b-overexpressing tumors, MSI-H/dMMR solid tumors, and PD-L1-negative disease.

Inflammatory and Autoimmune Diseases

The sponsor supports studies in immune-mediated disorders including atopic dermatitis, asthma, ulcerative colitis, antineutrophil cytoplasmic antibody-associated vasculitis, Behçet’s disease, juvenile idiopathic arthritis, juvenile psoriatic arthritis, and Sjögren’s syndrome.

  • Atopic dermatitis
  • Asthma
  • Ulcerative colitis
  • Vasculitis
  • Pediatric autoimmune disease

Additional interest extends to IgG4-related disease, generalized myasthenia gravis, and relapsing-remitting multiple sclerosis.

Cardiovascular and Metabolic Disorders

Amgen Inc. also funds research in cardiovascular disease, with studies in atherosclerotic cardiovascular disease, high cardiovascular risk, acute myocardial infarction, dyslipidemia, elevated lipoprotein(a), and heart failure with preserved or mildly reduced ejection fraction.

  • Atherosclerotic cardiovascular disease
  • Acute myocardial infarction
  • Dyslipidemia
  • Heart failure
  • Obesity-related cardiovascular risk

Its metabolic research includes overweight and obesity, type 2 diabetes mellitus, chronic weight management, and obstructive sleep apnea associated with excess body weight.

Neurology and Pain Disorders

The portfolio includes neurologic and pain-related conditions such as chronic migraine, episodic migraine, and relapsing-remitting multiple sclerosis, along with pediatric and adult immune-neurologic conditions.

  • Chronic migraine
  • Episodic migraine
  • Multiple sclerosis
  • Generalized myasthenia gravis

Research in this area also touches on central nervous system autoimmune disease and neuromuscular weakness.

Bone, Kidney, and Rare Disease Areas

Amgen Inc. funds studies in osteogenesis imperfecta, secondary hyperparathyroidism in pediatric patients with chronic kidney disease on hemodialysis, and other rare or specialized disorders affecting skeletal and mineral metabolism.

  • Osteogenesis imperfecta
  • Chronic kidney disease
  • Secondary hyperparathyroidism
  • Thyroid eye disease

Its research also includes prurigo nodularis and moderate to severe plaque psoriasis, reflecting interest in chronic dermatologic and inflammatory conditions.

Sponsored Trials

Trial Name Country Status
A Comparative Study of ABP 234 and Pembrolizumab in Patients with Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerAustria AustriaBulgaria BulgariaFrance FranceGermany GermanyItaly ItalyPoland PolandSpain SpainRecruiting
A Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Safety, Tolerability, and Effect of Olpasiran on Coronary Artery Plaque Burden Assessed by Coronary Computed Tomography Angiography in Participants With Stable Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)Denmark DenmarkFrance FranceGermany GermanyItaly ItalySpain SpainThe Netherlands The NetherlandsRecruiting
A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus.Czechia CzechiaGermany GermanyHungary HungaryPoland PolandSpain SpainNot Recruiting
A Phase 2/3 Randomized Double‑Blind Placebo‑Controlled Study of Inebilizumab in Adults with Autoimmune HepatitisBelgium BelgiumBulgaria BulgariaCzechia CzechiaFrance FranceGermany GermanyGreece GreeceHungary HungaryItaly ItalyPoland PolandPortugal PortugalSpain SpainThe Netherlands The NetherlandsRecruiting
A Phase 3 Long-term Extension Study of Apremilast in Pediatric Patients with Behçet’s Disease-Associated Oral Ulcers or Juvenile Psoriatic ArthritisGreece GreeceItaly ItalySpain SpainRecruiting
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV)Austria AustriaBelgium BelgiumBulgaria BulgariaCzechia CzechiaDenmark DenmarkFinland FinlandFrance FranceGermany GermanyGreece GreeceHungary HungaryItaly ItalyPoland PolandPortugal PortugalRomania RomaniaSlovakia SlovakiaSpain SpainSweden SwedenThe Netherlands The NetherlandsNot Recruiting
A Phase 3 Randomized, Double-blind,Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants with Obstructive Sleep Apnea not on Positive Airway Pressure Therapy and Living with Overweight or Obesity (MARITIME-OSA-2)Czechia CzechiaFrance FranceGermany GermanyHungary HungaryPoland PolandSpain SpainRecruiting
A Phase 3 Study of Xaluritamig versus Cabazitaxel or Second Androgen Receptor-Directed Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With ChemotherapyAustria AustriaBelgium BelgiumDenmark DenmarkFrance FranceGermany GermanyGreece GreeceItaly ItalyPoland PolandSpain SpainSweden SwedenThe Netherlands The NetherlandsNot Recruiting
A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Ignite)Croatia CroatiaCzechia CzechiaGermany GermanyGreece GreeceHungary HungaryItaly ItalyLatvia LatviaPoland PolandPortugal PortugalSlovakia SlovakiaSpain SpainThe Netherlands The NetherlandsNot Recruiting
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND)Austria AustriaBelgium BelgiumBulgaria BulgariaCroatia CroatiaCzechia CzechiaDenmark DenmarkEstonia EstoniaFinland FinlandFrance FranceGermany GermanyGreece GreeceHungary HungaryItaly ItalyLatvia LatviaPoland PolandPortugal PortugalRomania RomaniaSlovakia SlovakiaSlovenia SloveniaSpain SpainSweden SwedenThe Netherlands The NetherlandsNot Recruiting
1–10 of 90
1 / 9

Data & Insights

science
Molecule Portfolio
Compounds under investigation
9
Exclusive Molecules
out of 76 total (12% not shared with other sponsors)

This sponsor works with 76 molecules, of which 9 are not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
57%
Return partnership rate
913 of 1600 sites collaborated multiple times

This sponsor has worked with 1600 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Neoplasms42 trials
    856 other sponsors
  • 2.
    Immune System Diseases14 trials
    330 other sponsors
  • 3.
    Nutritional and Metabolic Diseases9 trials
    219 other sponsors
  • 4.
    Respiratory Tract Diseases6 trials
    280 other sponsors
  • 5.
    Cardiovascular Diseases4 trials
    365 other sponsors
  • 6.
    Nervous System Diseases4 trials
    455 other sponsors
  • 7.
    Digestive System Diseases3 trials
    283 other sponsors
  • 8.
    Eye Diseases3 trials
    138 other sponsors
  • 9.
    Skin and Connective Tissue Diseases3 trials
    251 other sponsors
  • 10.
    Congenital, Hereditary, and Neonatal Diseases and Abnormalities2 trials
    167 other sponsors
  • 11.
    Musculoskeletal Diseases2 trials
    243 other sponsors
  • 12.
    Hemic and Lymphatic Diseases1 trial
    254 other sponsors
  • 13.
    Immune System Phenomena1 trial
    16 other sponsors
  • 14.
    Immune system processes1 trial
    67 other sponsors
  • 15.
    Not possible to specify1 trial
    226 other sponsors

Partnered Research Centres

1600 centres
location_city
assignment1
"Ospedale San Giovanni di Dio, Clinica Dermatologica"
Address
Via Ospedale 54, 9124 Cagliari
Learn morearrow_forward
location_city
assignment13
251 Air Force General Hospital
Address
Kanellopoulou Avenue 3, 115 25 Athens
Learn morearrow_forward
location_city
assignment61
4 Wojskowy SzpitaKliniczny Z Polikliniką Samodzielny Publiczny ZakładOpieki ZdrowotneWe Wrocławiu
Address
Ul. Rudolfa Weigla 5, 53-114 Wroclaw
Learn morearrow_forward
location_city
assignment24
401 General Military Hospital Of Athens
Address
Panagioti Kanellopoulou Av 1, 115 25 Athens
Learn morearrow_forward
location_city
assignment22
A.O. Krankenhaus St. Josef Braunau GmbH
Address
Ringstrasse 60, 5280 Braunau am Inn
Learn morearrow_forward
location_city
assignment108
A.O.U. Policlinico G. Martino Di Messina
Address
Via Consolare Valeria N 1, 98124 Messina
Learn morearrow_forward
Page 1 of 267

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Amgen Inc..

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.